|19th October 2020||John Gordon Freund||190,053||Open or private sale||$22.00||$4,181,166.00|
|5th October 2020||Trevor Hallam||9,182||Exercise of derivative||$4.36||$40,033.52|
|28th September 2020||Trevor Hallam||975||Open or private sale||$10.26||$10,006.72|
|25th September 2020||Trevor Hallam||2,381||Payment by withholding||$10.30||$24,524.30|
|25th September 2020||William J Newell||13,219||Payment by withholding||$10.30||$136,155.70|
|25th September 2020||Trevor Hallam||11,019||Exercise of derivative||$0.00|
|25th September 2020||William J Newell||25,252||Exercise of derivative||$0.00|
|25th September 2020||Arturo Md Molina||2,976||Payment by withholding||$10.30||$30,652.80|
|25th September 2020||Arturo Md Molina||8,609||Exercise of derivative||$0.00|
|25th September 2020||Trevor Hallam||3,810||Payment by withholding||$10.30||$39,243.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility.